Total
0
Shares
Medibio (ASX:MEB) - Managing Director, Claude Solitario - The Market Herald
Managing Director, Claude Solitario
Source: Cyber Clinic
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medibio (MEB) has entered a Clinical Trial Agreement (CTA) with MedBridge Healthcare for its Sleep Analysis of Depression Burden (SADB) trial
  • The analysis aims to identify clinical depressive burden in patients who suffer from sleep disturbance
  • MedBridge is a leading provider of sleep lab management services in the U.S and performs over 70,000 sleep disorder diagnostic procedures every year
  • The parties are now fast-tracking patient recruitment
  • Company shares ended the day 10 per cent in the green to close for 1.1 cents

Medibio (MEB) has entered a Clinical Trial Agreement (CTA) with MedBridge Healthcare for its Sleep Analysis of Depression Burden (SADB) trial.

This analysis aims to identify clinical depressive burden in patients who suffer from sleep disturbance.

MedBridge is an America-based, leading provider of sleep laboratory management services. It operates over 130 sleep disorder diagnostic centres and performs over 70,000 sleep disorder diagnostic procedures every year to provide long-term care for patients with sleep disorders.

"We are delighted to have MedBridge as a partner for our Sleep Analysis of Depressive Burden trial. Their expertise and reputation in sleep medicine in the United States is exemplary, and the size of MedBridge’s operations will help ensure that our SADB trial will be undertaken quickly and efficiently," Medibio Managing Director Claude Solitario said.

MedBridge, in collaboration with Ohio Sleep Solutions in Columbus, will coordinate research guidelines and services for the SADB trial to help accelerate patient recruitment.

"The objective identification of depression in patients that suffer certain sleep disorders is an unmet need and we are pleased to be working with Medibio to fast-track patient recruitment for the SADB trial," MedBridge Chief Development Officer John Mathias said.

Company shares ended the day 10 per cent in the green to close for 1.1 cents.

MEB by the numbers
More From The Market Herald
Jayex Healthcare (ASX:JHL) - Executive Chairman, Michael Boyd - The Market Herald

" Jayex Healthcare (ASX:JHL) to divest hospital queue management business

Jayex Healthcare (JHL) has entered into an asset sale to divest its on-premises hospital queue management business.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert - The Market Herald

" Rhythm Biosciences’ (ASX:RHY) clinician network joins ColoSTAT trial

Rhythm Biosciences (RHY) has confirmed its network of clinicians is the latest group to join the company’s clinical trial for ColoSTAT.
Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

" Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

Shares in antiviral drug developer Island Pharmaceuticals (ILA) have jumped almost 150 per cent following the completion of a $7.5 million IPO.
Revasum (ASX:RVS) raises almost $7M via institutional entitlement offer

" Universal Biosensors (ASX:UBI) signs tech development deals

Universal Biosensors (UBI) has entered into exclusive agreements for the development of its biosensors.